HSE Grants Hospital Pricing Approval for High-Dose EYLEA in Ireland

Patients in Ireland facing vision loss from specific retinal conditions have a new treatment option. The Health Service Executive (HSE) has granted hospital pricing approval for EYLEA® (aflibercept) 114.3 mg/mL, a higher-dose solution for injection delivered via a pre-filled syringe.

This approval marks a significant step in managing chronic eye diseases, potentially reducing the frequency of clinic visits and the overall treatment burden for adult patients.

Understanding the Indications: nAMD and DMO

The approved high-dose aflibercept is specifically indicated for two primary conditions that can lead to severe visual impairment if left untreated:

• Neovascular (wet) age-related macular degeneration (nAMD): A rapid-progressing eye disease that can cause vision loss in as little as three months.
• Diabetic macular oedema (DMO): A condition where fluid builds up in the macula, causing visual impairment in patients with diabetes.

A Second-Line Treatment Approach

It’s critical to note that the HSE has approved EYLEA 8mg (aflibercept 114.3 mg/mL) as a second-line treatment. This means it is intended for adult patients with nAMD and DMO who have already undergone first-line treatment with bevacizumab.

The Clinical Advantage of Higher-Dose Aflibercept

The primary goal of introducing the 114.3 mg/mL concentration is to improve the patient experience without compromising vision outcomes. For many patients, the standard treatment for retinal diseases requires frequent, lifelong injections, which can be taxing both physically and logistically.

Dr. Tristan Cooper, Medical Director at Bayer Ireland, noted that EYLEA 8mg provides a higher-dose option that may help maintain vision outcomes for appropriate patients. Crucially, this higher dosage may enable longer intervals between injections for some individuals, thereby reducing the burden of frequent clinic visits.

Commitment to Patient Care in Ireland

The approval reflects an ongoing effort to integrate innovative medicines into the Irish healthcare system. John Woods, Managing Director of Bayer Ireland, welcomed the HSE’s decision, stating that the company remains committed to collaborating with the HSE and the clinical community to meet the needs of patients in Ireland, in accordance with national guidance and the approved indication.

Frequently Asked Questions

What is EYLEA?

EYLEA is a brand name for aflibercept, a medication used to treat certain types of vision loss by targeting the growth of abnormal blood vessels in the retina.

Why is “hospital pricing approval” important?

Hospital pricing approval from the HSE allows the medication to be funded and administered within the hospital setting, making it accessible to eligible patients through the public health system.

Will every patient receive the high-dose version?

No. This treatment is specifically for adult patients with nAMD or DMO who are appropriate candidates and have already tried first-line treatment with bevacizumab.

Looking Ahead

The approval of EYLEA 8mg represents a shift toward more personalized and efficient dosing schedules in ophthalmology. By potentially extending the time between injections, healthcare providers can improve the quality of life for patients while optimizing clinic resources. As this higher-dose option becomes available in Irish hospitals, clinicians will likely focus on identifying the specific patient subgroups who will benefit most from reduced injection frequency.